Peter Kuan-How Lin Acquires 26,667 Shares of Apollomics (NASDAQ:APLM) Stock

Apollomics Inc. (NASDAQ:APLM) CFO Peter Kuan-How Lin bought 26,667 shares of the stock in a transaction that occurred on Friday, August 14th. The shares were bought at an average price of $15.00 per share, for a total transaction of $400,005.00. Following the completion of the transaction, the chief financial officer directly owned 48,979 shares of the company’s stock, valued at $734,685. This represents a 119.52% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink.

Apollomics Stock Performance

APLM traded down $0.04 during midday trading on Monday, reaching $23.36. The company had a trading volume of 35,072 shares, compared to its average volume of 30,338. The business has a 50-day moving average of $18.24 and a two-hundred day moving average of $17.30. Apollomics Inc. has a 1 year low of $3.66 and a 1 year high of $42.12.

Analyst Ratings Changes

Separately, Weiss Ratings cut shares of Apollomics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 28th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.

Hedge Funds Weigh In On Apollomics

A hedge fund recently bought a new stake in Apollomics stock. Kestra Advisory Services LLC bought a new stake in shares of Apollomics Inc. (NASDAQ:APLM) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 4,380 shares of the company’s stock, valued at approximately $82,000. Kestra Advisory Services LLC owned 0.40% of Apollomics at the end of the most recent quarter. Hedge funds and other institutional investors own 19.13% of the company’s stock.

About Apollomics

Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.